{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T11:51:52Z","timestamp":1790077912059,"version":"4.0.1"},"reference-count":8,"publisher":"American Society for Microbiology","issue":"7","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2011,7]]},"abstract":"ABSTRACT<\/jats:title>\n \n Caspofungin (CFG) was tested in neutropenic and corticosteroid-immunosuppressed mice challenged with a lethal sinopulmonary inoculum of\n Rhizopus oryzae<\/jats:named-content>\n . Compared to untreated controls, CFG administered at 1 mg\/kg of body weight\/day significantly improved survival (54% versus 19%;\n P<\/jats:italic>\n = 0.003) and reduced median\n R. oryzae<\/jats:named-content>\n fungal burden by 1.5 log\n 10<\/jats:sub>\n for conidial equivalent DNA in neutropenic but not corticosteroid-immunosuppressed animals. CFG administered at 16 mg\/kg\/day was not significantly better than a saline control for treatment of invasive pulmonary mucormycosis (IPM) in either neutropenic or corticosteroid-immunosuppressed animals.\n <\/jats:p>","DOI":"10.1128\/aac.01812-10","type":"journal-article","created":{"date-parts":[[2011,5,3]],"date-time":"2011-05-03T02:42:03Z","timestamp":1304390523000},"page":"3584-3587","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":14,"title":["Efficacy of Caspofungin in Neutropenic and Corticosteroid-Immunosuppressed Murine Models of Invasive Pulmonary Mucormycosis"],"prefix":"10.1128","volume":"55","author":[{"given":"Russell E.","family":"Lewis","sequence":"first","affiliation":[{"name":"Division of Clinical and Experimental Pharmacology, University of Houston College of Pharmacy, Houston, Texas"},{"name":"Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas M.D. Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Leventakos","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas M.D. Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangling","family":"Liao","sequence":"additional","affiliation":[{"name":"Division of Clinical and Experimental Pharmacology, University of Houston College of Pharmacy, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios P.","family":"Kontoyiannis","sequence":"additional","affiliation":[{"name":"Division of Clinical and Experimental Pharmacology, University of Houston College of Pharmacy, Houston, Texas"},{"name":"Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas M.D. Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.73.1.494-503.2005"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.2.721-727.2005"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1086\/597615"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01222-09"},{"key":"e_1_3_2_6_2","first-page":"129","article-title":"Murine model of invasive aspergillosis","volume":"118","author":"Lewis R. E.","year":"2005","unstructured":"LewisR. E. WiederholdN. P.. 2005. Murine model of invasive aspergillosis. Methods Mol. Med. 118:129\u2013142.","journal-title":"Methods Mol. Med."},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1000549"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1086\/589857"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.2.830-832.2005"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01812-10","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01812-10","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T23:31:58Z","timestamp":1645486318000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01812-10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":8,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["10.1128\/AAC.01812-10"],"URL":"https:\/\/doi.org\/10.1128\/aac.01812-10","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7]]},"assertion":[{"value":"2010-12-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2011-04-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2011-06-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}